JP2013501762A5 - - Google Patents

Download PDF

Info

Publication number
JP2013501762A5
JP2013501762A5 JP2012524262A JP2012524262A JP2013501762A5 JP 2013501762 A5 JP2013501762 A5 JP 2013501762A5 JP 2012524262 A JP2012524262 A JP 2012524262A JP 2012524262 A JP2012524262 A JP 2012524262A JP 2013501762 A5 JP2013501762 A5 JP 2013501762A5
Authority
JP
Japan
Prior art keywords
floating granule
floating
granule according
group
alkaline agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012524262A
Other languages
English (en)
Japanese (ja)
Other versions
JP6068142B2 (ja
JP2013501762A (ja
Filing date
Publication date
Priority claimed from FR0955641A external-priority patent/FR2949061B1/fr
Application filed filed Critical
Publication of JP2013501762A publication Critical patent/JP2013501762A/ja
Publication of JP2013501762A5 publication Critical patent/JP2013501762A5/ja
Application granted granted Critical
Publication of JP6068142B2 publication Critical patent/JP6068142B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012524262A 2009-08-12 2010-08-11 浮遊微粒剤 Expired - Fee Related JP6068142B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0955641 2009-08-12
FR0955641A FR2949061B1 (fr) 2009-08-12 2009-08-12 Microgranules flottants
PCT/FR2010/051691 WO2011018582A2 (fr) 2009-08-12 2010-08-11 Microgranulés flottants

Publications (3)

Publication Number Publication Date
JP2013501762A JP2013501762A (ja) 2013-01-17
JP2013501762A5 true JP2013501762A5 (https=) 2015-06-11
JP6068142B2 JP6068142B2 (ja) 2017-01-25

Family

ID=42115979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012524262A Expired - Fee Related JP6068142B2 (ja) 2009-08-12 2010-08-11 浮遊微粒剤

Country Status (34)

Country Link
US (1) US8916202B2 (https=)
EP (1) EP2464333B1 (https=)
JP (1) JP6068142B2 (https=)
KR (2) KR20170119743A (https=)
CN (1) CN102548541B (https=)
AR (1) AR077864A1 (https=)
AU (1) AU2010283608B9 (https=)
BR (1) BR112012003289B1 (https=)
CA (1) CA2771053C (https=)
CL (1) CL2012000376A1 (https=)
CY (1) CY1118119T1 (https=)
DK (1) DK2464333T3 (https=)
EA (1) EA023532B1 (https=)
ES (1) ES2588430T3 (https=)
FR (1) FR2949061B1 (https=)
HR (1) HRP20161149T1 (https=)
HU (1) HUE030027T2 (https=)
IL (1) IL218072A (https=)
IN (1) IN2012DN01864A (https=)
LT (1) LT2464333T (https=)
MA (1) MA33523B1 (https=)
MX (1) MX2012001878A (https=)
NZ (1) NZ598468A (https=)
PE (1) PE20120805A1 (https=)
PL (1) PL2464333T3 (https=)
PT (1) PT2464333T (https=)
SG (1) SG180305A1 (https=)
SI (1) SI2464333T1 (https=)
SM (1) SMT201600347B (https=)
TN (1) TN2012000068A1 (https=)
TW (1) TWI478731B (https=)
UA (1) UA107361C2 (https=)
WO (1) WO2011018582A2 (https=)
ZA (1) ZA201201711B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
FR2938431B1 (fr) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9321956B2 (en) 2012-11-28 2016-04-26 Halliburton Energy Services, Inc. Methods for hindering the settling of particulates in a subterranean formation
US9790774B2 (en) 2014-01-02 2017-10-17 Halliburton Energy Services, Inc. Generating and maintaining conductivity of microfractures in tight formations by generating gas and heat
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
WO2017018996A1 (en) 2015-07-24 2017-02-02 Halliburton Energy Services, Inc. Microbubbles for heat and/or gas generation in subterranean formations
US10301917B2 (en) 2015-07-24 2019-05-28 Halliburton Energy Services, Inc. Microbubbles for treatment chemical delivery in subterranean formations
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP3737353A1 (en) 2017-12-18 2020-11-18 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019126216A1 (en) 2017-12-18 2019-06-27 Tris Phama, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11337919B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
NL2024652B1 (en) * 2020-01-10 2021-09-07 Stabican B V Process for preparing cannabinoid-containing particles
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276418A (en) * 1975-12-19 1977-06-27 Microbial Chem Res Found Method of preparing foamable micro-capsule preparations
US4101650A (en) * 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
JPS62195323A (ja) * 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
IT1248588B (it) 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
IT1266565B1 (it) 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5824339A (en) 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6214386B1 (en) * 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
FR2762213B1 (fr) * 1997-04-18 1999-05-14 Synthelabo Composition pharmaceutique a retention gastrique
SE9702533D0 (sv) * 1997-07-01 1997-07-01 Astra Ab New oral formulation
JP3447042B2 (ja) 1997-07-23 2003-09-16 フロイント産業株式会社 単一物質球形粒の製造方法
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
DK1140061T3 (da) 1998-12-23 2003-08-25 Orphan Medical Inc Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi
FR2797185B1 (fr) 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
BR0212019A (pt) 2001-08-06 2005-08-09 Euro Celtique Sa Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
FR2829932B1 (fr) 2001-09-21 2006-11-24 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs et produit obtenu
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
BR0314036A (pt) 2002-09-04 2005-07-12 Ranbaxy Lab Ltd Apresentações farmacêuticas com mascaramento de sabor e processo para sua preparação
CN1703200B (zh) 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
US20050214372A1 (en) 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US8193211B2 (en) 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
CN101534808A (zh) 2005-06-27 2009-09-16 拜维尔实验室国际有限公司 丁氨苯丙酮盐的改良释放配制品
HUE053838T2 (hu) * 2005-08-24 2021-07-28 Endo Pharmaceuticals Inc Nyújtott felszabadulású nabulfin-készítmények
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
WO2008134071A1 (en) 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
EP1962844A2 (en) * 2005-12-20 2008-09-03 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
ZA200807571B (en) 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
EP2192892A2 (en) * 2007-07-27 2010-06-09 Depomed, Inc. Pulsatile gastric retentive dosage forms
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
FR2938431B1 (fr) * 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments

Similar Documents

Publication Publication Date Title
JP2013501762A5 (https=)
JP2012508784A5 (https=)
NZ598468A (en) Floating microgranules
HRP20191911T1 (hr) Granule gama-hidroksibutirične kiseline
ES2307463T3 (es) Forma de dosificación de combinación que contiene un agente reductor del colesterol, un inhibidor de la renina-angiotensina, y aspirina.
JP2005508959A5 (https=)
CA2952406A1 (en) Solid formulation and method for preventing or reducing coloration thereof
WO2008131149A3 (en) Crystal forms of saxagliptin and processes for preparing same
JP2006298933A5 (https=)
CA2952405A1 (en) Solid formulation and method for stabilizing the same
WO2013093630A3 (en) Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
JP2005538104A5 (https=)
JP2014005302A5 (https=)
JP2013529072A5 (https=)
HRP20171384T1 (hr) Farmaceutski pripravak
WO2008114800A8 (en) Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile
JP2011037832A5 (https=)
WO2011048553A2 (en) Pharmaceutical compositions of pde-5 inhibitors and dapoxetine
HRP20200512T2 (hr) Formulacije koje sadrže linaklotid za oralnu primjenu
RU2006118689A (ru) Содержащий фармацевтический агент состав с покрытием
JP2007509891A5 (https=)
JP2004531399A5 (https=)
WO2007072495A3 (en) Coated tablets having prolonged gastric retention
JP2008516004A5 (https=)
PL375919A1 (en) Coated peroxygen compounds with controlled release, a process for their preparation and their use